| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | X97O9FTB92 |
| InChI Key | SNHCRNMVYDHVDT-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C17H17N3O |
| Molecular Weight | 279.34 |
| AlogP | 3.71 |
| Hydrogen Bond Acceptor | 4.0 |
| Hydrogen Bond Donor | 0.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 38.25 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 21.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| DISRUPTING AGENT | Tubulin disrupting agent | PubMed |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase EGFR family
|
- | 3 | - | - | - | |
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase PDGFR family
|
- | 6 | - | - | - | |
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase VEGFR family
|
- | 8 | - | - | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Glioblastoma | 2 | D005909 | ClinicalTrials |
| Neoplasms | 1 | D009369 | ClinicalTrials |
| Brain Neoplasms | 1 | D001932 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 827031-83-4 |
| ChEMBL | CHEMBL492399 |
| DrugBank | DB05585 |
| FDA SRS | X97O9FTB92 |
| PDB | 88U |
| PubChem | 11414799 |
| SureChEMBL | SCHEMBL2232326 |
| ZINC | ZINC000035978229 |